
X
Calliditas hits $90m jackpot as biotech IPO craze continues
https://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
Hoping for $100m, biotech raises under $3.5 million on stock market
Massachusetts-based company will test the waters for biotech sector